ALN-CFB

siRNA targeting complement factor B · Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALN-CFB, covering 2026-03-17 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor [Phase 1, Phase 2]

See pricing